Simultaneous Determination of Busulphan in Plasma Samples by Liquid Chromatography‐electrospray Ionization Mass Spectrometry Utilizing Microextraction in Packed Syringe (MEPS) as On‐line Sample Preparation Method
- 1 October 2007
- journal article
- research article
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 30 (20) , 3029-3041
Abstract
Busulphan is an alkylating agent used in high doses as preparative regimen before stem cell transplantation (SCT). Busulphan has a narrow therapeutic window and under‐ or overdosing may have a fatal outcome for the patient. Therapeutic drug monitoring followed by dose adjustment is currently used to adjust the exposure to busulphan. This is an important issue to optimise and individualise high dose therapy with busulphan. However, this approach is limited to centres with experienced personal measuring busulphan plasma concentrations. An automated and easy‐to‐handle method for measurement of busulphan plasma concentrations may facilitate and wide‐spread drug monitoring approach and thus improve the outcome of the patients undergoing SCT. Microextraction in packed syringe (MEPS) in combination with liquid chromatography and electrospray ionization mass spectrometric detection (LC‐MS/LC‐MS‐MS) to quantify busulphan in human plasma samples without derivatization was developed. MEPS is a new miniaturised, solid‐phase extraction technique that can be connected on‐line to GC or LC without any modifications. In MEPS approximately 1 mg of the solid packing material is inserted into a syringe (100–250 µL) as a plug. The validation of the method showed that the selectivity, accuracy and precision for the method were satisfactory. This is well in line with the international criteria for the study validation. The present method has shortened extraction time considerably and the method is fully automated, which benefits therapeutic drug monitoring of busulphan in SCT.Keywords
This publication has 21 references indexed in Scilit:
- Plasma Concentration Monitoring of BusulfanClinical Pharmacokinetics, 2000
- An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic diseaseBone Marrow Transplantation, 2000
- An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in childrenBone Marrow Transplantation, 1997
- Pharmacokinetic Optimisation of Cancer ChemotherapyClinical Pharmacokinetics, 1997
- Busulfan bioavailabilityBlood, 1994
- Busulfan disposition below the age of three: alteration in children with lysosomal storage diseaseBlood, 1993
- Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?Blood, 1992
- Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacologyCancer Chemotherapy and Pharmacology, 1991
- Gas chromatographic—mass spectrometric assay for busulfan in biological fluids using a deuterated internal standardJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Gas chromatographic determination of busulfan in plasma with electron-capture detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1983